Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 7/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597037 | 0.90 | GSK3B (0.37) | DRD2KDM2BROCK2DRD3 | |
| SCHEMBL5596515 | 0.85 | DRD2 (0.39) | DRD2ROCK2DRD3 | |
| SCHEMBL5596830 | 0.84 | DRD2 (0.36) | DRD2ROCK2DRD3 | |
| SCHEMBL5596793 | 0.84 | DRD2 (0.47) | DRD2KDM2BDRD3 | |
| SCHEMBL5596494 | 0.84 | DRD2 (0.36) | DRD2ROCK2DRD3 | |
| SCHEMBL5596645 | 0.84 | DRD2 (0.40) | DRD2ROCK2DRD3 | |
| SCHEMBL5596490 | 0.84 | DRD2 (0.32) | DRD2 | |
| SCHEMBL5596954 | 0.83 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL5596672 | 0.83 | OPRL1 (0.36) | DRD3 | |
| SCHEMBL5597147 | 0.83 | DRD2 (0.41) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | MTOR 1041/4885BTK 2694/4885UCHL1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.